Attendee search 

J Rich Capital Inc. is an investment banking boutique with offices in Shanghai and Silicon Valley. Established in 2008, we specialize in mergers and acquisitions, capital raising, and asset management services within biotech, pharmaceutical, and real estate industries. Our expansive capital management capabilities as well as our deep understanding of the China market differentiate us from our peers in the financial industry.

纳米抗体研发,肿瘤免疫治疗

薄荷天使基金

生物科技公司

国内一线投行

聚焦表观遗传学为核心的产品开发

The project focuses on the research and development of anti-tumor photosensitizing drugs for photodynamic therapy, creating a research and development technology platform for photosensitizing drugs, and conducting clinical development and transformation of anti-tumor photosensitizing drugs. The new anti-tumor photosensitizer drugs developed by our team exhibited excellent tumor enrichment and high efficacy of photodynamic therapy. They have great potential for clinical development and application.

世界500强医药企业，关注疫苗，糖尿病和创新药物

康为同创集团成立于2006年，位于北京市密云区经济开发区内，主要从事特种传动设备、电机电气、高端智能装备、智能传感器、智能芯片等的研发、生产、制造，是集产、学、研于一体的大型智能生产制造企业。产品广泛应用于轨道交通、商用航空器、基础工业、智能城市等诸多领域。

企业从成立之日起始终秉承“用户第一、质量第一、信誉第一、智能第一、双赢第一”的原则。已成功申请为国家高新技术企业，并取得国际铁路行业IRIS认证证书。集团公司经多年发展已初步建立起以智能设计为先导的智能化生产制造企业。为适应智能事业的需要，集团公司不断为客户提高更优质的服务。

We are the flagship subsidiary of China Resources Group, engaging in the research and development, manufacturing, distribution and retail of a broad range of pharmaceutical and healthcare products.In 2018, our total revenue is HK$ 189.7 billion.
Currently CR Pharma Group is one of the TOP 3 pharmacetucial group in China, and our core competences is capabilities are marketing&sales(3000+ Sales Reps for RX and 3000+ Sales Reps for OTC and healthcare products, local Regulatory Affairs(Dedicated RA team), and great manufacturing facilities(40+ manufacturing sites in China, including API and finished products of all dosage forms, 4 sites are approved by US FDA and EMEA).
As a listed company in HK, CR Pharma has estalished consodiated business reputation in healtcare industry and capital market. And currently, nearly all top 50 MNC pharmacetical companies are our business partner in China, and business scope includes JV, Licensing, Commercial Distribution.